Category: Press Releases

Radyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences Commercialization

Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Southern Research, a Birmingham-based contract research organization with more than 80 years of experience in drug discovery and development. This partnership marks a significant milestone in the advancement of life sciences commercialization in the Southeast region. The collaboration aims to leverage the strengths of both organizations to offer a comprehensive umbrella offering to clients, with fully integrated preclinical services.

By combining Southern Research’s longstanding reputation for cutting-edge laboratory research with Radyus Research’s innovative planning and project management approaches, this alliance will provide a one-stop solution for clients seeking to navigate the complexities of life sciences commercialization.

“We are very excited to continue creating synergy within the Southeast’s biotech community,” said Josh Carpenter, CEO at Southern Research. “The team at Radyus Research brings unique expertise that complements our own. Together, we will work closely to help our partners move their therapeutics forward with a compelling suite of combined services.”

This partnership’s primary goal is to foster a thriving ecosystem for life sciences companies in the region. By offering a comprehensive array of services under one roof, clients can benefit from seamless integration of preclinical services, including but not limited to drug discovery, development, clinical, regulatory, and manufacturing support.

“We are thrilled to join forces with Southern Research in this strategic partnership,” said Marta New, CEO at Radyus Research. “Our combined expertise will not only enhance the services we offer but will also create new opportunities for life sciences companies to flourish in our region. This partnership underscores our commitment to driving innovation and accelerating the journey from concept to market.”

Maria Thacker Goethe, President & CEO at Georgia Bio, is also excited about this joint regional ecosystem effort: “The Southeast region is rapidly advancing in terms of startups with game-changing and impactful technology innovations. Effective partnerships like this between Radyus Research and Southern Research are critical to the growing landscape in the region and will demonstrate innovative ways for collaboration.”

Clients can expect a seamless experience with access to a full spectrum of consulting, project management, and laboratory testing services tailored to meet their unique needs in drug development. From initial research and development to preclinical toxicology testing and regulatory approval, the collaborative efforts of Southern Research and Radyus Research will provide comprehensive support every step of the way.

About Radyus Research

Radyus Research is a drug development group dedicated to accelerating clients’ drug programs into the clinic. With a commitment to excellence and innovation, Radyus Research offers a range of services aimed at providing comprehensive drug development planning and project management. Acting as an operating R&D partner to biotech companies, academic startups, and seed venture capital firms, we manage their programs through IND-enabling studies, IND application, and initiation of first in human trials. Our extensive expertise spans various modalities in immunology, oncology, infectious diseases, metabolic diseases, and neurosciences. We are based in Atlanta, Georgia, serving clients across the globe in over 12 countries.

Southern Research opens new Station 41 biotech incubator for startups

Today, Southern Research marked the official opening of its Station 41 biotech incubator, which is one of four programs that make up the newly launched Station 41 biotech commercialization hub. The incubator provides wet lab space and office space, shared lab equipment and services to support biotech startup growth.

The incubator is located in a newly renovated space on Southern Research’s campus on Birmingham’s Southside.

“In the past, Birmingham has lost companies and jobs to other markets because we did not have available commercial wet lab space,” said Josh Carpenter, Ph.D.,CEO of Southern Research. “With this incubator, we are beginning to meet this need. Under the same roof, we are also providing early-stage biotech and pharma companies with unique access to our renowned drug discovery and development capabilities here at Southern Research.”

In addition to their own office and lab space, companies in the incubator have preferred access to Southern Research screening facilities, and they are able to connect with staff experts who can help them move their product forward.

The incubator space is a part of Southern Research’s Station 41 biotech commercialization hub, which also includes the Accelerator, the Venture Studio and the Therapeutics Development Fund, which all exist to help biotech startups with funding, expertise and resources.

“Opening Station 41 marks another great stride in making Birmingham the premier biotech commercialization hub of the Southeast,” said UAB President Ray L. Watts. “Here we will nurture local innovation and entrepreneurs, and attract new businesses and talent to our region, helping make Birmingham and Alabama all the more competitive in the 21st century global economy.”

The Station 41 programs are a cornerstone of efforts to expand biotech in Birmingham, which got a big boost last year with Birmingham’s designation as a Regional Tech Hub.

“Just three months ago, we announced the designation of Birmingham as a federal Tech Hub by the Biden-Harris Administration,” U.S. Rep. Terri Sewell said.  “Today, I am beyond thrilled to join Southern Research and UAB as we celebrate the official opening of the Station 41 biotech incubator. The launch of this project is a major step forward in our shared mission of cementing Birmingham as a center for innovation. I have no doubt that it will attract leading biotech companies, new jobs, and cutting-edge research to the Magic City. I extend my thanks to Southern Research, UAB, and the many partners who made this project possible.”

The incubator has space for 12 companies, and it is targeting companies involved in treating and diagnosing diseases—especially those aligned with Southern Research’s core focus areas, which include cancer, infectious diseases and chronic diseases.

Four companies have already moved in to the space, and the incubator leaders expect to fill it within the year.

“Our company is working to revolutionize the way the medical community treats and prevents chronic and infectious lung diseases,” said Gaurav Mehta, CEO of Alveolus Bio, one of the businesses located in the incubator. “Our partnership with Southern Research’s Station 41 incubator lines us up for success. We are thankful and excited to be part of Birmingham’s growing and promising life science ecosystem.”

Another member, Adjuvax, is a startup focused on the early-stage development of a new generation of vaccines made possible by the novel vaccine compounds discovered at UAB in chemistry professor Pengfei Wang’s lab.

“The Station 41 incubator is an ideal place for Adjuvax because of its well-designed lab space, shared equipment, and valuable onsite services, which are crucial for startups,” Wang said. “The convenient location of the Station 41 incubator on the Southern Research campus will also help Adjuvax establish more collaborations with Southern Research in vaccine development.”

The contractor on the project was Brasfield & Gorrie.

“Our team is passionate about building projects that serve the communities where we live and work, and Southern Research takes that a step further,” said Brasfield & Gorrie Regional Vice President and Division Manager Robby Hayes. “Southern Research’s efforts affect the world as they develop world-class solutions that address modern-day health threats. By providing space to biotech entrepreneurs, Southern Research is creating opportunity for others as well as further developing that biotech ecosystem in our city and state. We’re thrilled that we were able to construct this essential lab space.”



About Southern Research: Founded in Birmingham in 1941, Southern Research is a non-profit scientific research organization that employs 250 scientists and professional staff. In its 80-year legacy of moving science, the organization has helped shape modern cancer treatment practices, including developing seven FDA-approved cancer drugs and testing more than half of active chemotherapies in the United States. Southern Research has conducted more than $30 million in coronavirus research since 2020, including collaborations on a COVID-19 vaccine currently in clinical trials, conducting thousands of PCR tests and refining the underlying chemistry of critical treatments. The organization is among the highest NIH-funded non-academic research centers in Alabama and has a $220 million annual economic impact. Visit for more information.